Formulation, In Vitro And In Vivo Evaluation Of Cosmetic Nano-Cream From Virgin Coconut Oil, Kojic Acid Dipalmitate And Emulium Kappa

Virgin Coconut Oil (VCO)-in-water stabilized by Emulium Kappa® (EK) as an emulsifier was used to prepare a cosmetic cream. Kojic acid dipalmitate (KDP) dissolved in VCO was the whitening ingredient. The final characteristic of the cream formulation depends on the ratio of the oil phase, emulsifier/coemulsifier and water which are considered as the main variables. Ternary phase diagram with contour graphics was used to assess the effects of variable changes. The system was designed by using Scheffe model

PREPARATION AND JUSTIFICATION OF NANOFIBRES-LOADED MAFENIDE USING ELECTROSPINNING TECHNIQUE TO CONTROL RELEASE

Objective: The primary objective was to fabricate a novel drug delivery system capable of providing a controlled and prolonged release of antibiotics. Methods: The experimental design was formulated using Design-Expert® software (version 13), enabling systematic and efficient fabrication process optimization. The study involved the preparation of various nanofiber formulations with different ratios of the three polymers to assess their impact on drug release behavior. Mafenide, a widely used antibiotic, was chosen as the model drug for this investigation. The electrospinning process allowed for producing uniform and fine nanofibers with a high surface area, ensuring a large drug-loading capacity. The synthesized nanofibers were characterized using scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR) to evaluate their morphology, chemical interactions, and thermal properties. The drug release kinetics of the antibiotic-loaded nanofibers were studied under different physiological conditions to assess their sustained release behavior. Results: The final nanofiber formula was successfully prepared using the electrospinning technique. The Fourier Transform Infrared Spectroscopy (FTIR) analysis was achieved to confirm the possibility of chemical interaction and bond formation between mafenide and the polymers. Present. The SEM picture of the optimized nanofiber formula showed the homogeneity and excellent entanglement of the electrospun nanofibers at a resolution of 5 µm. PVA/chitosan/HPMC and mafenide pure drug have been successfully fabricated with sufficient strength to resist swelling after absorbing wound exudate. The polymer network becomes more compact when chitosan and Hydroxypropyl Methyl Cellulose (HPMC) are combined with polyvinyl alcohol (PVA), enabling regulated swelling during solvent ingress. The polymer composite's three-dimensional network influenced how quickly the medication was released from the matrix. Sample 2's polymer network traps the medication, gradually releasing after controlled swelling, resulting in a sustained release profile compared to blank sample according to the cumulative release (%) study of mafenide loaded nanofiber and mafenide drug blank sample. Conclusion: This research successfully demonstrated the fabrication of sustained-release antibiotic nanofibers using electrospinning and three biocompatible polymers. The systematic optimization approach using Design-Expert® software proved effective in tailoring the drug release behavior of nanofibers. The developed drug delivery system holds great promise for pharmaceutical applications, particularly in improving antibiotic therapies and patient care.

Preparation And Characterization of Polyvinyl Alcohol Nanofiber Loaded With Mafenide For Sustain Release

This paper delves into the intricate process of preparing and characterizing Polyvinyl alcohol (PVA) nanofibers loaded with Mafenide to achieve sustained release functionality. The synthesis involves the careful integration of Mafenide, a pharmaceutical agent known for its antimicrobial properties, into PVA nanofibers. This combination holds promise for controlled drug delivery applications. The preparation begins with the electrospinning technique, a method widely employed for creating nanofibrous structures. During this process, the Mafenide is incorporated into the PVA matrix, forming a composite material. The choice of Polyvinyl alcohol as the base material is strategic, given its biocompatibility and excellent film-forming properties. The characterization phase involves a comprehensive analysis of the resulting nanofibers. Techniques such as scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR). are employed to examine the morphology and chemical composition of the nanofibrous system. These analyses provide insights into the structural integrity and the successful incorporation of Mafenide. The study focuses on the sustained release aspect, aiming to understand how the loaded Mafenide interacts within the PVA nanofibers over time. This sustained release mechanism is crucial for pharmaceutical applications, offering prolonged therapeutic effects and minimizing the need for frequent administration. The potential benefits of this research lie in the development of an efficient drug delivery system

Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility

The following research aimed to enhance solubility by loading candesartan cilexetil into nanosuspension. Candesartan cilexetil-loaded nanosuspension was prepared with the aid of Design-Expert® software. A technique of solvent evaporation was employed to produce nanosuspensions from hydroxyl propyl methyl cellulose (HPMC E5), polyvinyl pyrrolidone (PVP K-30), and poloxamer (PXM 188). The optimised nanosuspensions’ particle size and polydispersity index (PDI) were 64.65 nm and 0.059, respectively. The entrapment efficacy (EE %) and drug loading (DL %) were 86.75 and 10.17%, respectively. The atomic force microscopy (AFM) revealed spherical and smooth nanoparticles. The Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) revealed pure, crystalline and conjugated drugs inside the nanosuspension. The release study confirmed 90% release within 10 min. No significant changes in particle sizes over three months were found, indicating stable nanoparticles. Saturated solubility of the candesartan cilexetil powder and loaded nanosuspension was 63.3 ± 6 and 344.7 ± 16 µg.ml-1, respectively, revealing more than five times increase in solubility. Candesartan cilexetil-loaded nanosuspensions were successfully prepared using different combinations of PVP K-30, HPMC E-5 and PXM 188 in various concentrations. Solubility was enhanced by loading the payload into nanosuspensions

FORMULATION, ANALYSIS AND VALIDATION OF NANOSUSPENSIONS-LOADED VORICONAZOLE TO ENHANCE SOLUBILITY

Objective: This study aimed to enhance the solubility of voriconazole (VRZ) via loading to nanosuspensions using solvent /anti-solvent technique. The optimisation of independent variables (polymer concentrations) was carried out to achieve the desired particle size and maximise the percentage of entrapment efficiency (EE %) and drug loading (DL %) using Design-Expert® software. Methods: Design-Expert® software, version 13, was used to design and optimise nanosuspensions-loaded VRZ using 23 factorial designs. Concentrations of polyvinylpyrrolidone, hydroxypropyl methylcellulose and poloxamers were selected as independent variables to achieve ideal particle size, polydispersity index (PDI), entrapment efficacy (EE %) and drug loading (DL %). Atomic force microscopy (AFM), differential scanning calorimetry (DSC) and saturated solubility were used to assess the lyophilized nanoparticles. The compatibility between the drug and the polymers was studied using Fourier transform infrared spectroscopy (FTIR). Results: The particle size, PDI, EE %, and DL % were in the range of 15.6 – 145.6 nm, 0.010 - 0.120, 55.9 % - 91.9 %, and 6.68 - 36.76 %, respectively. The saturated solubility of nanosuspensions-loaded VRZ (NS-VRZ) relative to free VRZ was increased tenfold in DW and twelvefold in PBS (pH 7.4). DSC thermogram confirmed the incorporation of VRZ in the nanosuspensions. The AFM of NS-VRZ validated spherical tiny particle size with a smooth surface. There is no chemical interaction between VRZ and the polymers, according to an FTIR investigation. Conclusion: The solubility of VRZ was successfully enhanced by loading to nanosuspensions. The solvent/anti-solvent technique was proven to be cost-effective, easy to operate and suitable for the preparation of NS-VRZ using Design-Expert® software

A A COMPARATIVE STUDY OF QUALITY CONTROL TESTING ON CANDESARTAN CILEXETIL CONVENTIONAL TABLETS IN IRAQ

Objective: The present study was performed to compare the quality of conventional tablets loaded with candesartan cilexetil. The selected candesartan cilexetil tablets were commercialized in the Iraq market and produced by different companies.  Methods: Different batches of candesartan cilexetil oral tablets (the concentration of candesartan was 8 mg) were subjected to quality control tests. Tests included weight variation, friability, hardness, drug content, disintegration time and in vitro release study. The protocols of these tests were performed according to USP pharmacopeia. Results: The results, in this study, revealed that all the used batches of candesartan cilexetil oral tablets complied with the specification of USP pharmacopeia for weight uniformity, friability value (% loss) was<1. Hardness results of the tablets were 4.9-6.6 Kg/cm2, which was within the required limits (i.e. 4-8 Kg/cm2). Disintegration time was<15 min in both Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF). The percentage of drug content in all marketed tablets was found between 96.2 % and 99.8 %, reflecting compliance with the pharmacopeia limits (i.e. 85-115 %). An in vitro release study indicated that the release of all marketed tablets exceeds 80 % within 15 min. Conclusion: All the studied tablets, loaded with candesartan cilexetil, were produced within the standard criteria of tablet production. The quality control analysis of the selected tablets, in this study, revealed satisfactory pharmaceutical properties (including safety and effectiveness) that comply within the limits of USP pharmacopeia